share_log

花旗：予中国生物制药“买入”评级 目标价6.8港元

新浪港股 ·  Jul 26 12:09

花旗发布研究报告称，由于生物仿制药及创新药的销售强劲增长，预计中国生物制药（01177）上半年业绩表现理想，料盈利同比增长约10%。由于生物仿制药、G-CSF及Cataplasms的销量增加，预期公司下半年业绩将有较高的能见度。该行开启对公司30天上行催化观察，目标价6.8港元，评级“买入”。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment